Your browser doesn't support javascript.
loading
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma.
Mi, Jian-Qing; Zhao, Wanhong; Jing, Hongmei; Jin, Jie; Chen, Sai-Juan.
Afiliação
  • Mi JQ; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: jianqingmi@shsmu.edu.cn.
  • Zhao W; The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Jing H; Peking University Third Hospital, Beijing, China.
  • Jin J; First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China.
  • Chen SJ; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Eur J Cancer ; 188: 108-110, 2023 07.
Article em En | MEDLINE | ID: mdl-37229834
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article País de publicação: Reino Unido